Scientific Sessions 2024  /  Mixing it Up: Pulmonary Hypertension in Patients with Both Heart and Lung Disease  /  Debate: Patients with Group 2 and 3 PH should NOT Be Treated with PAH Therapies
Logo

American Heart Association

  2
  0

Final ID:

Debate: Patients with Group 2 and 3 PH should NOT Be Treated with PAH Therapies

  • Vachiery, Jean-luc  ( Erasme University Hospital , Brussels , Belgium )
  • Maron, Brad  ( University of Maryland , Sharon , Massachusetts , United States )
    • Author Disclosures:
    Jean-Luc Vachiery: DO have relevant financial relationships ; Consultant:GossamerBio:Active (exists now) ; Consultant:Insmed:Active (exists now) ; Consultant:Liquidia:Active (exists now) ; Consultant:Merck:Active (exists now) ; Consultant:Roivant:Active (exists now) | Brad Maron: DO have relevant financial relationships ; Consultant:Actelion:Active (exists now) ; Research Funding (PI or named investigator):Deerfield Company:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Mixing it Up: Pulmonary Hypertension in Patients with Both Heart and Lung Disease

Monday, 11/18/2024 , 08:00AM - 09:15AM

Cardiovascular Seminar

More abstracts on this topic:
Debate: Patients with Group 2 and Group 3 PH should be treated with PAH Therapies

Waxman Aaron, Mclaughlin Valerie

Mixed Group 2/3 and Group 3/2 Pulmonary Hypertension: Lessons Learned from PVDOMICS

Hemnes Anna, Leopold Jane, Rischard Franz

More abstracts from these authors:
Round Table

Vachiery Jean-luc

Panel Discussion

Maron Brad

You have to be authorized to contact abstract author. Please, Login
Not Available